المؤلفون: Oh DY, Milde J, Ham Y, Ramos Calderón JP, Wedde M, Dürrwald R, Duwe SC

المصدر: Infection and Drug Resistance, Vol Volume 16, Pp 949-959 (2023)

مصطلحات موضوعية: influenza viruses, antiviral resistance, phenotypic assay, genotypic assay, surveillance, neuraminidase, cap-dependent endonuclease, baloxavir marboxil, molecular resistance marker, Infectious and parasitic diseases, RC109-216

وصف الملف: electronic resource

العلاقة: https://www.dovepress.com/preparing-for-the-next-influenza-season-monitoring-the-emergence-and-s-peer-reviewed-fulltext-article-IDRTest; https://doaj.org/toc/1178-6973Test

الوصول الحر: https://doaj.org/article/f0f1b242b75544f7b039875b1ec295a8Test

المؤلفون: Duwe, SC, Schmidt, B, Gärtner, BC, Timm, J, Adams, O, Fickenscher, H, Schmidtke, M

المصدر: GMS Infectious Diseases; VOL: 9; DOC02 /20210430/

مصطلحات موضوعية: infection, neuraminidase, baloxavir, polymerase, resistance, ddc: 610

العلاقة: Agrawal U, Raju R, Udwadia ZF. Favipiravir: A new and emerging antiviral option in COVID-19. Med J Armed Forces India. 2020 Oct;76(4):370-6. DOI:10.1016/j.mjafi.2020.08.004; Alame MM, Massaad E, Zaraket H. Peramivir: A Novel Intravenous Neuraminidase Inhibitor for Treatment of Acute Influenza Infections. Front Microbiol. 2016 Mar;7:450. DOI:10.3389/fmicb.2016.00450; Antiviral drugs for influenza. Med Lett Drugs Ther. 2020 Jan 13;62(1589):1-4.; Asiedu-Bekoe F, Adu DA, Offei A. Mass oseltamivir prophylaxis halts pandemic influenza A H1N1 2009 outbreak in a secondary school in Ashanti Region, Ghana. Ghana Med J. 2012 Dec;46(4):219-24.; Baker J, Block SL, Matharu B, Burleigh Macutkiewicz L, Wildum S, Dimonaco S, Collinson N, Clinch B, Piedra PA. Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2). Pediatr Infect Dis J. 2020 Aug;39(8):700-5. DOI:10.1097/INF.0000000000002747; Baranovich T, Wong SS, Armstrong J, Marjuki H, Webby RJ, Webster RG, Govorkova EA. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J Virol. 2013 Apr;87(7):3741-51. DOI:10.1128/JVI.02346-12; Beigel JH, Bao Y, Beeler J, Manosuthi W, Slandzicki A, Dar SM, Panuto J, Beasley RL, Perez-Patrigeon S, Suwanpimolkul G, Losso MH, McClure N, Bozzolo DR, Myers C, Holley HP Jr, Hoopes J, Lane HC, Hughes MD, Davey RT; IRC003 Study Team. Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial. Lancet Infect Dis. 2017 Dec;17(12):1255-65. DOI:10.1016/S1473-3099(17)30476-0; Berner R; Deutsche Gesellschaft für Pädiatrische Infektiologie e.V. (DGPI). Aktualisierte Empfehlung der DGPI zur Diagnostik, Therapie und Prophylaxe der Infektion mit dem Neuen Influenza A/H1N1v-Virus bei Kindern und Jugendlichen. Berlin: DGPI; 2009 [last updated 2009 Nov 09]. Available from: https://www.aerztekammer-berlin.de/40presse/15_meldungen/00688_Schweinegrippe/00688_Aktualisierte_Empfehlungen_DGPI_zur_Therapie_und_Prophylaxe_bei_Kindern_und_Jugendlichen_20_August_2009.pdfTest; BioCryst. Ravipab: Peramivir injection. 2020. Available from: http://www.rapivab.comTest; Bischoff W, Russell G, Willard E, Stehle J Jr. Impact of a novel mobile high-efficiency particulate air-ultraviolet air recirculation system on the bacterial air burden during routine care. Am J Infect Control. 2019 Aug;47(8):1025-7. DOI:10.1016/j.ajic.2018.12.019; Bowles SK, Lee W, Simor AE, Vearncombe M, Loeb M, Tamblyn S, Fearon M, Li Y, McGeer A; Oseltamivir Compassionate Use Program Group. Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000. J Am Geriatr Soc. 2002 Apr;50(4):608-16. DOI:10.1046/j.1532-5415.2002.50153.x; Braun S, Behrens T, Kulp W, Eberle A, Greiner W, Ahrens W, von der Schulenburg JM. Neuraminidasehemmer in der Therapie und Postexpositionsprophylaxe der Influenza. Köln: DIMDI; 2005. (Health Technology Assessment; Bd. 25). Available from: https://portal.dimdi.de/de/hta/hta_berichte/hta116_bericht_de.pdfTest; Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin e.V. (DGP); Deutsche Gesellschaft für Infektiologie e.V. (DGI); Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. (PEG). Behandlung von erwachsenen Patienten mit ambulant erworbener Pneumonie und Prävention - Update 2016. S3-Leitlinie. AWMF-Registernummer 020-020. Berlin: AWMF; 2016.; Deutscher Bundestag. Antwort der Bundesregierung auf die Kleine Anfrage der Abgeordneten Kordula Schulz-Asche, Dr. Harald Terpe, Maria Klein-Schmeink, weiterer Abgeordneter und der Fraktion BÜNDNIS 90/ DIE GRÜNEN - Drucksache 18/1227 - Zweifel an der Wirksamkeit der Neuraminidasehemmer Tamiflu und Relenza. 2014 May 09. Available from: http://dipbt.bundestag.de/dip21/btd/18/013/1801384.pdfTest; Doll MK, Winters N, Boikos C, Kraicer-Melamed H, Gore G, Quach C. Safety and effectiveness of neuraminidase inhibitors for influenza treatment, prophylaxis, and outbreak control: a systematic review of systematic reviews and/or meta-analyses. J Antimicrob Chemother. 2017 Nov;72(11):2990-3007. DOI:10.1093/jac/dkx271; Dunning J, Baillie JK, Cao B, Hayden FG; International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC). Antiviral combinations for severe influenza. Lancet Infect Dis. 2014 Dec;14(12):1259-70. DOI:10.1016/S1473-3099(14)70821-7; Duwe S. Influenza viruses - antiviral therapy and resistance. GMS Infect Dis. 2017 Apr;5:Doc04. DOI:10.3205/id000030; Dziewiatkowski NA, Osmon EN, Chahine EB, Thornby KA. Baloxavir: A Novel Single-Dose Oral Antiviral for the Treatment of Influenza. Sr Care Pharm. 2019 Apr;34(4):243-52. DOI:10.4140/TCP.n.2019.243; Eisenberg RA, Jawad AF, Boyer J, Maurer K, McDonald K, Prak ET, Sullivan KE. Rituximab-treated patients have a poor response to influenza vaccination. J Clin Immunol. 2013 Feb;33(2):388-96. DOI:10.1007/s10875-012-9813-x; European Centre for Disease Prevention and Control. Expert opinion on neuraminidase inhibitors for the prevention and treatment of influenza - Review of recent systematic reviews and meta-analyses. Stockholm: ECDC; 2017. DOI:10.2900/01723; European Medicines Agency. Alpivab Peramivir. Amsterdam: EMA; 2018 [last updated 2020 Dec 09]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/alpivabTest; European Medicines Agency. Dectova Zanamivir. Amsterdam: EMA; 2019. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/dectovaTest; European Medicines Agency. Tamiflu oseltamivir. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/tamifluTest; European Medicines Agency. Xofluza (baloxavir marboxil) - EMA/648596/2020. Amsterdam: EMA; 2021. Available from: https://www.ema.europa.eu/en/documents/overview/xofluza-epar-medicine-overview_en.pdfTest; European Medicines Agency. Summary on compassionate use for iv zanamivir. London: EMA; 2011 Jun 23. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2011/03/WC500104028.pdfTest; Ewig S, Höffken G, Kern WV, Rohde G, Flick H, Krause R, Ott S, Bauer T, Dalhoff K, Gatermann S, Kolditz M, Krüger S, Lorenz J, Pletz M, de Roux A, Schaaf B, Schaberg T, Schütte H, Welte T. Behandlung von erwachsenen Patienten mit ambulant erworbener Pneumonie und Prävention - Update 2016 [Management of Adult Community-acquired Pneumonia and Prevention - Update 2016]. Pneumologie. 2016 Mar;70(3):151-200. DOI:10.1055/s-0042-101873; Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013 Nov;100(2):446-54. DOI:10.1016/j.antiviral.2013.09.015; Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, Kozaki K, Nomura N, Egawa H, Shiraki K. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother. 2005 Mar;49(3):981-6. DOI:10.1128/AAC.49.3.981-986.2005; Gärtner BC, Avery RK. Respiratory viral infections in solid organ transplant recipients - New insights from multicenter data. Am J Transplant. 2020 Nov 21. DOI:10.1111/ajt.16408; Gesellschaft für Virologie (GfV e.V.); Deutsche Vereinigung zur Bekämpfung der Viruskrankheiten (DVV e.V.). Virusinfektionen bei Organ- und allogen Stammzell-Transplantierten: Diagnostik, Prävention und Therapie. S2k-Leitlinie. AWMF-Registernummer 093-002. Berlin: AWMF; 2019. Available from: https://www.awmf.org/leitlinien/detail/ll/093-002.htmlTest; Giannella M, Rodríguez-Sánchez B, Roa PL, Catalán P, Muñoz P, García de Viedma D, Bouza E; the Gregorio Marañón Task Force for Pneumonia (GANG). Should lower respiratory tract secretions from intensive care patients be systematically screened for influenza virus during the influenza season? Crit Care. 2012;16(3):R104. DOI:10.1186/cc11387; Goldhill DH, Te Velthuis AJW, Fletcher RA, Langat P, Zambon M, Lackenby A, Barclay WS. The mechanism of resistance to favipiravir in influenza. Proc Natl Acad Sci U S A. 2018 Nov;115(45):11613-8. DOI:10.1073/pnas.1811345115; Govorkova EA, Webster RG. Combination chemotherapy for influenza. Viruses. 2010;2(8):1510-29. DOI:10.3390/v2081510; Gubareva LV, Mishin VP, Patel MC, Chesnokov A, Nguyen HT, De La Cruz J, Spencer S, Campbell AP, Sinner M, Reid H, Garten R, Katz JM, Fry AM, Barnes J, Wentworth DE. Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons. Euro Surveill. 2019 Jan;24(3):1800666. DOI:10.2807/1560-7917.ES.2019.24.3.1800666; Hagihara M, Kato Y, Kurumiya A, Takahashi T, Sakata M, Kato H, Sakanashi D, Yamada A, Suematsu H, Hirai J, Nishiyama N, Koizumi Y, Yamagishi Y, Mikamo H. The Prophylactic Effect of Anti-influenza Agents for an Influenza Outbreak in a University Hospital. Intern Med. 2018;57(4):497-501. DOI:10.2169/internalmedicine.8854-17; Hayden FG, Treanor JJ, Fritz RS, Lobo M, Betts RF, Miller M, Kinnersley N, Mills RG, Ward P, Straus SE. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA. 1999 Oct;282(13):1240-6. DOI:10.1001/jama.282.13.1240; Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, Ishida T, Sekino H, Yamada K, Portsmouth S, Kawaguchi K, Shishido T, Arai M, Tsuchiya K, Uehara T, Watanabe A; Baloxavir Marboxil Investigators Group. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med. 2018 Sep;379(10):913-23. DOI:10.1056/NEJMoa1716197; Hayden FG. Pandemic influenza: is an antiviral response realistic? Pediatr Infect Dis J. 2004 Nov;23(11 Suppl):S262-9. DOI:10.1097/01.inf.0000144680.39895.ce; Hideyuki Ikematsu, Naoki Kawai. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza. Expert Rev Anti Infect Ther. 2011 Oct;9(10):851-7. DOI:10.1586/eri.11.112; Hurt A, Komadina N, Deng YM, Kaye M, Sullivan S, Subbarao K, Barr I. Detection of adamantane-sensitive influenza A(H3N2) viruses in Australia, 2017: a cause for hope? Euro Surveill. 2017 Nov;22(47):17-00731. DOI:10.2807/1560-7917.ES.2017.22.47.17-00731; Hurt AC. Antiviral Therapy for the Next Influenza Pandemic. Trop Med Infect Dis. 2019 Apr;4(2):67. DOI:10.3390/tropicalmed4020067; Hurt AC, Kelly H. Debate Regarding Oseltamivir Use for Seasonal and Pandemic Influenza. Emerg Infect Dis. 2016 Jun;22(6):949-55. DOI:10.3201/eid2206.151037; Ikematsu H, Hayden FG, Kawaguchi K, Kinoshita M, de Jong MD, Lee N, Takashima S, Noshi T, Tsuchiya K, Uehara T. Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts. N Engl J Med. 2020 Jul;383(4):309-20. DOI:10.1056/NEJMoa1915341; Ison MG, Portsmouth S, Yoshida Y, Shishido T, Mitchener M, Tsuchiya K, Uehara T, Hayden FG. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2020;20(10):1204-14. DOI:10.1016/S1473-3099(20)30004-9; Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, Spencer EA, Onakpoya I, Mahtani KR, Nunan D, Howick J, Heneghan CJ. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2014 Apr;2014(4):CD008965. DOI:10.1002/14651858.CD008965.pub4; Jhung MA, D'Mello T, Pérez A, Aragon D, Bennett NM, Cooper T, Farley MM, Fowler B, Grube SM, Hancock EB, Lynfield R, Morin C, Reingold A, Ryan P, Schaffner W, Sharangpani R, Tengelsen L, Thomas A, Thurston D, Yousey-Hindes K, Zansky S, Finelli L, Chaves SS. Hospital-onset influenza hospitalizations - United States, 2010-2011. Am J Infect Control. 2014 Jan;42(1):7-11. DOI:10.1016/j.ajic.2013.06.018; Kawaguchi N, Koshimichi H, Ishibashi T, Wajima T. Evaluation of Drug-Drug Interaction Potential between Baloxavir Marboxil and Oseltamivir in Healthy Subjects. Clin Drug Investig. 2018 Nov;38(11):1053-60. DOI:10.1007/s40261-018-0697-2; Khandaker G, Rashid H, Zurynski Y, Richmond PC, Buttery J, Marshall H, Gold M, Walls T, Whitehead B, Elliott EJ, Booy R. Nosocomial vs community-acquired pandemic influenza A (H1N1) 2009: a nested case-control study. J Hosp Infect. 2012 Oct;82(2):94-100. DOI:10.1016/j.jhin.2012.07.006; Koszalka P, Tilmanis D, Roe M, Vijaykrishna D, Hurt AC. Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012-2018. Antiviral Res. 2019 Apr;164:91-6. DOI:10.1016/j.antiviral.2019.02.007; Kumagai Y, Murakawa Y, Hasunuma T, Aso M, Yuji W, Sakurai T, Noto M, Oe T, Kaneko A. Lack of effect of favipiravir, a novel antiviral agent, on QT interval in healthy Japanese adults. Int J Clin Pharmacol Ther. 2015 Oct;53(10):866-74. DOI:10.5414/CP202388; Lackenby A, Besselaar TG, Daniels RS, Fry A, Gregory V, Gubareva LV, Huang W, Hurt AC, Leang SK, Lee RTC, Lo J, Lollis L, Maurer-Stroh S, Odagiri T, Pereyaslov D, Takashita E, Wang D, Zhang W, Meijer A. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017. Antiviral Res. 2018 Sep;157:38-46. DOI:10.1016/j.antiviral.2018.07.001; Lehnert R, Pletz M, Reuss A, Schaberg T. Antiviral Medications in Seasonal and Pandemic Influenza. Dtsch Arztebl Int. 2016;113(47):799-807. DOI:10.3238/arztebl.2016.0799; Louie JK, Yang S, Acosta M, Yen C, Samuel MC, Schechter R, Guevara H, Uyeki TM. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin Infect Dis. 2012 Nov;55(9):1198-204. DOI:10.1093/cid/cis636; Macesic N, Kotsimbos TC, Kelly P, Cheng AC. Hospital-acquired influenza in an Australian sentinel surveillance system. Med J Aust. 2013 Apr;198(7):370-2. DOI:10.5694/mja12.11687; Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol. 2004 Nov;78(22):12665-7. DOI:10.1128/JVI.78.22.12665-12667.2004; Mertens T. Influenza - Prophylaxe und Therapie: Für Neuraminidasehemmer gibt es noch keinen Ersatz. Dtsch Arztebl. 2015 Mar;112(11):A-464/B-394/C-86.; Mifsud EJ, Hayden FG, Hurt AC. Antivirals targeting the polymerase complex of influenza viruses. Antiviral Res. 2019 Sep;169:104545. DOI:10.1016/j.antiviral.2019.104545; Mishin VP, Patel MC, Chesnokov A, De La Cruz J, Nguyen HT, Lollis L, Hodges E, Jang Y, Barnes J, Uyeki T, Davis CT, Wentworth DE, Gubareva LV. Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir1. Emerg Infect Dis. 2019 Oct;25(10):1969-72. DOI:10.3201/eid2510.190607; Mitchell R, Taylor G, McGeer A, Frenette C, Suh KN, Wong A, Katz K, Wilkinson K, Amihod B, Gravel D; Canadian Nosocomial Infection Surveillance Program. Understanding the burden of influenza infection among adults in Canadian hospitals: a comparison of the 2009-2010 pandemic season with the prepandemic and postpandemic seasons. Am J Infect Control. 2013 Nov;41(11):1032-7. DOI:10.1016/j.ajic.2013.06.008; Mizumoto K, Nishiura H, Yamamoto T. Effectiveness of antiviral prophylaxis coupled with contact tracing in reducing the transmission of the influenza A (H1N1-2009): a systematic review. Theor Biol Med Model. 2013 Jan;10:4. DOI:10.1186/1742-4682-10-4; Mombelli M, Lang BM, Neofytos D, Aubert JD, Benden C, Berger C, Boggian K, Egli A, Soccal PM, Kaiser L, Hirzel C, Pascual M, Koller M, Mueller NJ, van Delden C, Hirsch HH, Manuel O; Swiss Transplant Cohort Study. Burden, epidemiology, and outcomes of microbiologically confirmed respiratory viral infections in solid organ transplant recipients - a nationwide, multi-season prospective cohort study. Am J Transplant. 2020 Oct 31. DOI:10.1111/ajt.16383; Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med. 2005 Sep;353(13):1363-73. DOI:10.1056/NEJMra050740; Moscona A. Oseltamivir resistance - disabling our influenza defenses. N Engl J Med. 2005 Dec;353(25):2633-6. DOI:10.1056/NEJMp058291; Noshi T, Kitano M, Taniguchi K, Yamamoto A, Omoto S, Baba K, Hashimoto T, Ishida K, Kushima Y, Hattori K, Kawai M, Yoshida R, Kobayashi M, Yoshinaga T, Sato A, Okamatsu M, Sakoda Y, Kida H, Shishido T, Naito A. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. Antiviral Res. 2018 Dec;160:109-17. DOI:10.1016/j.antiviral.2018.10.008; Oh DY, Hurt AC. A Review of the Antiviral Susceptibility of Human and Avian Influenza Viruses over the Last Decade. Scientifica (Cairo). 2014;2014:430629. DOI:10.1155/2014/430629; Omoto S, Speranzini V, Hashimoto T, Noshi T, Yamaguchi H, Kawai M, Kawaguchi K, Uehara T, Shishido T, Naito A, Cusack S. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci Rep. 2018 Jun;8(1):9633. DOI:10.1038/s41598-018-27890-4; Oxford JS. Zanamivir (Glaxo Wellcome). IDrugs. 2000 Apr;3(4):447-59.; Principi N, Camilloni B, Alunno A, Polinori I, Argentiero A, Esposito S. Drugs for Influenza Treatment: Is There Significant News? Front Med (Lausanne). 2019 May;6:109. DOI:10.3389/fmed.2019.00109; Robert Koch-Institut. Influenza (Teil 1): Erkrankungen durch saisonale Influenzaviren - RKI-Ratgeber. Berlin: RKI; 2016 [last updated 2016 Feb 12]. Available from: https://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_Influenza_saisonal.html#doc2382022bodyText1Test; Robert Koch-Institut. Bericht zur Epidemiologie der Influenza in Deutschland Saison 2018/19. Berlin: RKI; 2019. DOI:10.25646/6232; Robert Koch-Institut. Bericht zur Epidemiologie der Influenza in Deutschland Saison 2017/18. Berlin: RKI; 2018. DOI:10.17886/rkipubl-2018-003; Rodríguez A, Díaz E, Martín-Loeches I, Sandiumenge A, Canadell L, Díaz JJ, Figueira JC, Marques A, Alvarez-Lerma F, Vallés J, Baladín B, García-López F, Suberviola B, Zaragoza R, Trefler S, Bonastre J, Blanquer J, Rello J; H1N1 SEMICYUC Working Group. Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A. J Antimicrob Chemother. 2011 May;66(5):1140-9. DOI:10.1093/jac/dkq511; Schmidtke M, Mertens T; Gesellschaft für Virologie e.V. (GfV); Deutsche Vereinigung zur Bekämpfung der Viruskrankheiten e.V. (DVV); Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. (PEG). Brauchen wir die Grippemittel Tamiflu und Relenza? GMS Infect Dis. 2014;2:Doc06. DOI:10.3205/id000014; Suess T, Remschmidt C, Schink S, Luchtenberg M, Haas W, Krause G, Buchholz U. Facemasks and intensified hand hygiene in a German household trial during the 2009/2010 influenza A(H1N1) pandemic: adherence and tolerability in children and adults. Epidemiol Infect. 2011 Dec;139(12):1895-901. DOI:10.1017/S0950268810003006; Sugaya N. Widespread use of neuraminidase inhibitors in Japan. J Infect Chemother. 2011;17(5):595-601. DOI:10.1007/s10156-011-0288-0; Sugaya N, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother. 2010 Jun;54(6):2575-82. DOI:10.1128/AAC.01755-09; Taieb V, Ikeoka H, Ma FF, Borkowska K, Aballéa S, Tone K, Hirotsu N. A network meta-analysis of the efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors for the treatment of influenza in otherwise healthy patients. Curr Med Res Opin. 2019 Aug;35(8):1355-64. DOI:10.1080/03007995.2019.1584505; Takashita E, Ichikawa M, Morita H, Ogawa R, Fujisaki S, Shirakura M, Miura H, Nakamura K, Kishida N, Kuwahara T, Sugawara H, Sato A, Akimoto M, Mitamura K, Abe T, Yamazaki M, Watanabe S, Hasegawa H, Odagiri T. Human-to-Human Transmission of Influenza A(H3N2) Virus with Reduced Susceptibility to Baloxavir, Japan, February 2019. Emerg Infect Dis. 2019;25(11):2108-11. DOI:10.3201/eid2511.190757; Takashita E, Kawakami C, Morita H, Ogawa R, Fujisaki S, Shirakura M, Miura H, Nakamura K, Kishida N, Kuwahara T, Mitamura K, Abe T, Ichikawa M, Yamazaki M, Watanabe S, Odagiri T; Influenza Virus Surveillance Group Of Japan. Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018. Euro Surveill. 2019 Jan;24(3):1800698. DOI:10.2807/1560-7917.ES.2019.24.3.1800698; Takashita E, Morita H, Ogawa R, Nakamura K, Fujisaki S, Shirakura M, Kuwahara T, Kishida N, Watanabe S, Odagiri T. Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil. Front Microbiol. 2018 Dec;9:3026. DOI:10.3389/fmicb.2018.03026; Takashita E, Kawakami C, Ogawa R, Morita H, Fujisaki S, Shirakura M, Miura H, Nakamura K, Kishida N, Kuwahara T, Ota A, Togashi H, Saito A, Mitamura K, Abe T, Ichikawa M, Yamazaki M, Watanabe S, Odagiri T. Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019. Euro Surveill. 2019 Mar;24(12):1900170. DOI:10.2807/1560-7917.ES.2019.24.12.1900170; Taylor G, Mitchell R, McGeer A, Frenette C, Suh KN, Wong A, Katz K, Wilkinson K, Amihod B, Gravel D; Canadian Nosocomial Infection Surveillance Program. Healthcare-associated influenza in Canadian hospitals from 2006 to 2012. Infect Control Hosp Epidemiol. 2014 Feb;35(2):169-75. DOI:10.1086/674858; Toyama Chemical. The New Drug Application Approval of "AVIGAN® Tablet 200mg" in Japan for the anti-influenza virus drug. 2014 Mar 24. Available from: http://fftc.fujifilm.co.jp/en/news/news140324e.htmlTest; Uehara T, Hayden FG, Kawaguchi K, Omoto S, Hurt AC, De Jong MD, Hirotsu N, Sugaya N, Lee N, Baba K, Shishido T, Tsuchiya K, Portsmouth S, Kida H. Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza. J Infect Dis. 2020 Jan;221(3):346-55. DOI:10.1093/infdis/jiz244; von Lilienfeld-Toal M, Berger A, Christopeit M, Hentrich M, Heussel CP, Kalkreuth J, Klein M, Kochanek M, Penack O, Hauf E, Rieger C, Silling G, Vehreschild M, Weber T, Wolf HH, Lehners N, Schalk E, Mayer K. Community acquired respiratory virus infections in cancer patients - Guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for haematology and Medical Oncology. Eur J Cancer. 2016 Nov;67:200-12. DOI:10.1016/j.ejca.2016.08.015; Wang J, Pielak RM, McClintock MA, Chou JJ. Solution structure and functional analysis of the influenza B proton channel. Nat Struct Mol Biol. 2009 Dec;16(12):1267-71. DOI:10.1038/nsmb.1707; Watanabe A, Chang SC, Kim MJ, Chu DW, Ohashi Y; MARVEL Study Group. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial. Clin Infect Dis. 2010 Nov;51(10):1167-75. DOI:10.1086/656802; WHO. Practical guidance for national influenza centres establishing or implementing neuraminidase inhibitor susceptibility surveillance. Update 2018. Geneva: WHO; 2018. Available from: http://www.who.int/influenza/gisrs_laboratory/antiviral_susceptibility/practical_guidance/enTest/; Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus, Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, Hayden FG, Nguyen DH, de Jong MD, Naghdaliyev A, Peiris JS, Shindo N, Soeroso S, Uyeki TM. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med. 2008 Jan;358(3):261-73. DOI:10.1056/NEJMra0707279; Wutzler P, Kossow KD, Lode H, Ruf BR, Scholz H, Vogel GE; Expert Group, German Association for the Control of Virus Diseases and Paul-Ehrlich Society of Germany. Antiviral treatment and prophylaxis of influenza in primary care: German recommendations. J Clin Virol. 2004 Oct;31(2):84-91. DOI:10.1016/j.jcv.2004.05.009; http://dx.doi.org/10.3205/id000071Test; http://nbn-resolving.de/urn:nbn:de:0183-id0000716Test; http://www.egms.de/en/journals/id/2021-9/id000071.shtmlTest

الإتاحة: https://doi.org/10.3205/id000071Test
https://doi.org/10.1016/j.mjafi.2020.08.004Test
https://doi.org/10.3389/fmicb.2016.00450Test
https://doi.org/10.1097/INF.0000000000002747Test
https://doi.org/10.1128/JVI.02346-12Test
https://doi.org/10.1016/S1473-3099Test(17)30476-0
https://doi.org/10.1016/j.ajic.2018.12.019Test
https://doi.org/10.1046/j.1532-5415.2002.50153.xTest
https://doi.org/10.1093/jac/dkx271Test
https://doi.org/10.1016/S1473-3099Test(14)70821-7